This page shows the latest cariprazine news and features for those working in and with pharma, biotech and healthcare.
For AbbVie, Allergan’s most interesting programmes are a clutch central nervous system (CNS) candidates including antidepressant Vraylar (cariprazine) – which it says has blockbuster potential – as well as oral CGRP inhibitors
Valent claimed a US approval for this drug last year. Gedeon Richter got the nod for Reagila (cariprazine) as a treatment for schizophrenia - which follows US approval in 2015 - and Chiesi
EU. cariprazine. Vraylar. schizophrenia / bipolar disorder. dopamine D3/D2 receptor partial agonist.
Vraylar (cariprazine) is a dopamine D2, D3 receptor partial agonist and was turned down by the FDA in 2013, with the agency requesting more data including another clinical trial despite acknowledging ... Analysts at Canaccord Genuity have indicated they
FDA announced it will take another three months to review cariprazine for schizophrenia. ... end of 2013, despite concluding that cariprazine showed efficacy in the two indications. .
in the summer, as well as two novel antipsychotics - Otsuka/Lundbeck's brexpiprazole and cariprazine from Actavis and Gedeon Richter. ... Cariprazine was turned down by the FDA towards the end of 2013 but has just shown activity in a new phase III trial,
More from news
Approximately 2 fully matching, plus 12 partially matching documents found.
Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...